Market Summary
USD71.86-0.40
Market Closed-0.55%
INCY Alerts
INCY Stock Price
INCY RSI Chart
INCY Valuation
INCY Price/Sales (Trailing)
INCY Profitability
INCY Fundamentals
INCY Revenue
INCY Earnings
Price Action
52 Week Range
65.0786.29
(Low)(High)
Last 7 days
-2.8%
Last 30 days
-8.5%
Last 90 days
-11.7%
Trailing 12 Months
-6.8%
INCY Financial Health
INCY Investor Care
Peers (Alternatives to Incyte)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
GILD | 98.0B | 27.3B | -7.18% | 37.83% | 21.33 | 3.59 | -0.09% | -26.23% |
MRNA | 57.1B | 19.3B | -7.28% | -16.95% | 6.83 | 2.97 | 4.29% | -31.47% |
INCY | 16.0B | 3.4B | -8.45% | -6.80% | 46.99 | 4.72 | 13.67% | -64.09% |
EXAS | 11.8B | 2.1B | 7.92% | 0.14% | -18.87 | 5.64 | 17.95% | -4.68% |
| MID-CAP | ||||||||
EXEL | 5.9B | 1.6B | 4.36% | -14.51% | 32.36 | 3.66 | 12.27% | -21.11% |
SYNH | 3.5B | 5.4B | -8.08% | -56.83% | 13.04 | 0.64 | 3.46% | 13.48% |
DNLI | 3.1B | 108.5M | -20.63% | -31.77% | -9.51 | 28.59 | 122.90% | -12.19% |
ARWR | 2.5B | 278.3M | -25.09% | -47.78% | -16.35 | 9.08 | 92.72% | 15.56% |
| SMALL-CAP | ||||||||
AVXL | 664.8M | - | -14.80% | -31.35% | -13.28 | 291.16 | -34.21% | -22.31% |
NVAX | 499.9M | 2.0B | -38.13% | -92.75% | -0.76 | 0.25 | 72.89% | 62.27% |
PGEN | 193.6M | 80.7M | -28.46% | -55.92% | 6.84 | 4.15 | 13.30% | 130.72% |
SRNE | 143.9M | 60.3M | -71.28% | -88.95% | -0.29 | 2.39 | 17.51% | -38.93% |
TENX | 16.2M | - | -31.53% | -19.40% | -0.25 | - | - | -67.11% |
NNVC | 14.8M | - | -16.13% | -29.35% | -2.15 | - | - | 20.96% |
Financials for Incyte
| Income Statement (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Revenue | 1.9% | 3,395 | 3,331 | 3,320 | 3,115 | 2,986 |
| S&GA Expenses | 4.9% | 1,002 | 956 | 880 | 795 | 740 |
| R&D Expenses | 1.8% | 1,586 | 1,557 | 1,508 | 1,505 | 1,458 |
| Costs and Expenses | 3.9% | 2,815 | 2,711 | 2,603 | 2,511 | 2,400 |
| EBITDA | -5.7% | 600 | 636 | 694 | 634 | - |
| EBITDA Margin | -7.5% | 0.18* | 0.19* | 0.21* | 0.20* | - |
| Earnings Before Taxes | -6.9% | 529 | 569 | 629 | 572 | 570 |
| EBT Margin | -8.7% | 0.16* | 0.17* | 0.19* | 0.18* | - |
| Interest Expenses | -3.1% | 3.00 | 3.00 | 3.00 | 2.00 | 2.00 |
| Net Income | -61.1% | 341 | 876 | 945 | 933 | 949 |
| Net Income Margin | -61.8% | 0.10* | 0.26* | 0.28* | 0.30* | - |
| Free Cahsflow | 21.0% | 970 | 802 | 760 | 759 | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Assets | 6.0% | 5,841 | 5,510 | 5,319 | 5,054 | 4,933 |
| Current Assets | 7.1% | 4,093 | 3,821 | 3,626 | 3,288 | 3,119 |
| Cash Equivalents | 9.7% | 2,951 | 2,691 | 2,435 | 2,257 | 2,057 |
| Inventory | -8.4% | 42.00 | 46.00 | 55.00 | 36.00 | 28.00 |
| Net PPE | 3.3% | 739 | 716 | 721 | 729 | 724 |
| Goodwill | 0% | 156 | 156 | 156 | 156 | 156 |
| Liabilities | 14.6% | 1,471 | 1,284 | 1,234 | 1,191 | 1,163 |
| Current Liabilities | 14.9% | 1,157 | 1,007 | 927 | 886 | 854 |
| Shareholder's Equity | 3.4% | 4,370 | 4,227 | 4,085 | 3,863 | 3,770 |
| Retained Earnings | 6.1% | -437 | -465 | -578 | -739 | -777 |
| Additional Paid-In Capital | 1.5% | 4,792 | 4,721 | 4,689 | 4,626 | 4,567 |
| Accumulated Depreciation | 5.3% | 202 | 192 | 186 | 176 | - |
| Shares Outstanding | 0.1% | 223 | 222 | 222 | 221 | 221 |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Cashflow From Operations | 21.0% | 970 | 802 | 760 | 759 | 749 |
| Share Based Compensation | 2.4% | 188 | 184 | 181 | 179 | 183 |
| Cashflow From Investing | 36.5% | -78.54 | -123 | -128 | -164 | -207 |
| Cashflow From Financing | -107.4% | -0.79 | 11.00 | 6.00 | -6.56 | 6.00 |
Risks for INCY
What is the probability of a big loss on INCY?
76.2%
Probability that Incyte stock will be more than 20% underwater in next one year
24.2%
Probability that Incyte stock will be more than 30% underwater in next one year.
12.3%
Probability that Incyte stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does INCY drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Incyte was unfortunately bought at previous high price.
Drawdowns
Returns for INCY
Cumulative Returns on INCY
12.5%
10-Year Cumulative Returns
0.4%
7-Year Cumulative Returns
-2.9%
5-Year Cumulative Returns
4.4%
3-Year Cumulative Returns
What are the long-term rolling returns for INCY?
FIve years rolling returns for Incyte.
Annualized Returns
Which funds bought or sold INCY recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-03-15 | B. Riley Wealth Advisors, Inc. | reduced | -0.28 | 42,835 | 259,835 | 0.01% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -40.84 | -5,398,430 | 13,416,600 | 0.01% |
2023-03-10 | BAILLIE GIFFORD & CO | unchanged | - | 2,253 | 13,253 | -% |
2023-03-06 | NORTH STAR ASSET MANAGEMENT INC | unchanged | - | 155,632 | 911,632 | 0.06% |
2023-03-06 | Rockefeller Capital Management L.P. | added | 71.5 | 1,115,000 | 2,159,000 | 0.01% |
2023-02-28 | Voya Investment Management LLC | added | 1.74 | 2,233,340 | 12,103,300 | 0.02% |
2023-02-24 | SRS Capital Advisors, Inc. | unchanged | - | 365 | 1,365 | -% |
2023-02-24 | National Pension Service | reduced | -4.2 | 3,226,530 | 24,017,000 | 0.05% |
2023-02-24 | NATIXIS | reduced | -89.37 | -9,121,060 | 1,340,940 | 0.01% |
2023-02-22 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | unchanged | - | 232,000 | 1,364,000 | 0.01% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
INCY Alerts
Incyte News
Schedule 13G FIlings of Incyte
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Mar 15, 2023 | baker bros. advisors lp | 16.3% | 36,280,967 | SC 13D/A | |
| Feb 14, 2023 | dodge & cox | 8.7% | 19,362,935 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 9.68% | 21,533,818 | SC 13G/A | |
| Jan 25, 2023 | blackrock inc. | 8.9% | 19,836,617 | SC 13G/A | |
| Mar 10, 2022 | baker bros. advisors lp | 16.4% | 36,269,307 | SC 13D/A | |
| Feb 14, 2022 | baker bros. advisors lp | 15.7% | 34,851,571 | SC 13D/A | |
| Feb 14, 2022 | price t rowe associates inc /md/ | 3.2% | 7,271,688 | SC 13G/A | |
| Feb 14, 2022 | dodge & cox | 7.5% | 16,657,586 | SC 13G | |
| Feb 10, 2022 | vanguard group inc | 9.48% | 20,944,759 | SC 13G/A | |
| Feb 04, 2022 | wellington management group llp | 4.08% | 9,008,491 | SC 13G/A |
INCY Fair Value
Incyte fair value in different scenarios
The table shows the Fair Value estimates for Incyte for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
| Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
|---|---|---|---|---|---|
| Very Low Inflation | 48.22 -32.90% | 63.57 -11.54% | 84.15 17.10% | 115.61 60.88% | 150.79 109.84% |
| Current Inflation | 44.44 -38.16% | 57.60 -19.84% | 74.84 4.15% | 101.28 40.94% | 130.89 82.15% |
| Very High Inflation | 39.77 -44.66% | 50.39 -29.88% | 63.83 -11.17% | 84.62 17.76% | 107.94 50.21% |
Historical Incyte Fair Value Estimates
Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price
Recent SEC filings of Incyte
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Mar 15, 2023 | 4 | Insider Trading | |
| Mar 15, 2023 | SC 13D/A | 13D - Major Acquisition | |
| Feb 21, 2023 | 4 | Insider Trading | |
| Feb 15, 2023 | 4 | Insider Trading | |
| Feb 14, 2023 | SC 13G/A | Major Ownership Report | |
| Feb 09, 2023 | SC 13G/A | Major Ownership Report | |
| Feb 08, 2023 | SC 13G/A | Major Ownership Report | |
| Feb 07, 2023 | 8-K | Current Report | |
| Feb 07, 2023 | 10-K | Annual Report | |
| Feb 02, 2023 | 4 | Insider Trading |
Latest Insider Trading transactions for INCY
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-03-13 | BAKER BROS. ADVISORS LP | acquired | 909,600 | 22.74 | 40,000 | - |
2023-02-16 | Dhanak Dashyant | acquired | 241,596 | 65.42 | 3,693 | evp & chief scientific officer |
2023-02-13 | Stamoulis Christiana | sold (taxes) | -94,414 | 80.08 | -1,179 | evp & chief financial officer |
2023-01-31 | Pasquale Maria E | acquired | 59,973 | 74.78 | 802 | evp & general counsel |
2023-01-31 | Pasquale Maria E | sold | -67,416 | 84.06 | -802 | evp & general counsel |
2023-01-30 | Pasquale Maria E | sold | -5,086,570 | 84.7422 | -60,024 | evp & general counsel |
2023-01-30 | Pasquale Maria E | acquired | 4,405,220 | 73.391 | 60,024 | evp & general counsel |
2023-01-26 | Iyengar Vijay K | sold | -595,000 | 85.00 | -7,000 | evp, gmapps |
2023-01-26 | Iyengar Vijay K | acquired | 480,340 | 68.62 | 7,000 | evp, gmapps |
2023-01-26 | Dhanak Dashyant | sold | -205,615 | 85.00 | -2,419 | evp & chief scientific officer |
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
INCY Income Statement
2022-09-30CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
| Revenues: | ||||
| Total revenues | $ 823,303 | $ 812,987 | $ 2,467,935 | $ 2,123,414 |
| Costs and expenses: | ||||
| Cost of product revenues (including definite-lived intangible amortization) | 54,584 | 39,869 | 147,834 | 107,117 |
| Research and development | 384,007 | 334,945 | 1,084,576 | 985,352 |
| Selling, general and administrative | 266,460 | 190,704 | 729,321 | 513,358 |
| (Gain) loss on change in fair value of acquisition-related contingent consideration | (21,893) | 2,910 | (12,198) | 13,068 |
| Collaboration loss sharing | 1,769 | 9,149 | 9,055 | 29,476 |
| Total costs and expenses | 684,927 | 577,577 | 1,958,588 | 1,648,371 |
| Income from operations | 138,376 | 235,410 | 509,347 | 475,043 |
| Other income (expense), net | 11,513 | 1,948 | 13,295 | 4,931 |
| Interest expense | (641) | (439) | (1,999) | (1,156) |
| Unrealized loss on long term investments | (660) | (27,450) | (72,142) | (28,394) |
| Income before provision for income taxes | 148,588 | 209,469 | 448,501 | 450,424 |
| Provision for income taxes | 35,813 | 27,730 | 136,302 | 65,694 |
| Net income | $ 112,775 | $ 181,739 | $ 312,199 | $ 384,730 |
| Net income per share: | ||||
| Basic (in USD per share) | $ 0.51 | $ 0.82 | $ 1.41 | $ 1.75 |
| Diluted (in USD per share) | $ 0.50 | $ 0.82 | $ 1.40 | $ 1.73 |
| Shares used in computing net income per share: | ||||
| Basic (in shares) | 222,415 | 220,845 | 221,801 | 220,243 |
| Diluted (in shares) | 224,175 | 222,248 | 223,626 | 222,113 |
| Product revenues, net | ||||
| Revenues: | ||||
| Total revenues | $ 713,010 | $ 594,013 | $ 1,982,682 | $ 1,673,974 |
| Product royalty revenues | ||||
| Revenues: | ||||
| Total revenues | 110,293 | 183,974 | 350,253 | 404,440 |
| Milestone and contract revenues | ||||
| Revenues: | ||||
| Total revenues | $ 0 | $ 35,000 | $ 135,000 | $ 45,000 |
INCY Balance Sheet
2022-09-30CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) | Sep. 30, 2022 | Dec. 31, 2021 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 2,690,622,000 | $ 2,057,440,000 |
| Marketable securities—available-for-sale (amortized cost $292,941 and $291,871 as of September 30, 2022 and December 31, 2021, respectively; allowance for credit losses $0 as of September 30, 2022 and December 31, 2021) | 286,500,000 | 290,752,000 |
| Accounts receivable | 618,188,000 | 616,300,000 |
| Inventory | 45,869,000 | 27,904,000 |
| Prepaid expenses and other current assets | 179,932,000 | 126,278,000 |
| Total current assets | 3,821,111,000 | 3,118,674,000 |
| Restricted cash and investments | 1,601,000 | 1,720,000 |
| Long-Term Investments | 149,124,000 | 221,266,000 |
| Inventory | 55,264,000 | 29,034,000 |
| Property and equipment, net | 715,733,000 | 723,920,000 |
| Finance lease right-of-use assets, net | 26,679,000 | 27,548,000 |
| Other intangible assets, net | 134,603,000 | 150,755,000 |
| Goodwill | 155,593,000 | 155,593,000 |
| Deferred income tax asset | 426,840,000 | 467,538,000 |
| Other assets, net | 23,666,000 | 37,304,000 |
| Total assets | 5,510,214,000 | 4,933,352,000 |
| Current liabilities: | ||
| Accounts payable | 163,175,000 | 172,110,000 |
| Accrued compensation | 106,309,000 | 108,962,000 |
| Accrued and other current liabilities | 699,814,000 | 533,595,000 |
| Finance lease liabilities | 3,112,000 | 2,635,000 |
| Acquisition-related contingent consideration | 34,186,000 | 37,006,000 |
| Total current liabilities | 1,006,596,000 | 854,308,000 |
| Acquisition-related contingent consideration | 171,814,000 | 206,994,000 |
| Finance lease liabilities | 30,476,000 | 31,632,000 |
| Other liabilities | 74,677,000 | 70,414,000 |
| Total liabilities | 1,283,563,000 | 1,163,348,000 |
| Commitments and contingencies (Note 14) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 5,000,000 shares authorized; none issued or outstanding | 0 | 0 |
| Common stock, $0.001 par value; 400,000,000 shares authorized; 222,454,839 and 221,084,433 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively | 222,000 | 221,000 |
| Additional paid-in capital | 4,721,166,000 | 4,567,111,000 |
| Accumulated other comprehensive loss | (29,062,000) | (19,454,000) |
| Accumulated deficit | (465,675,000) | (777,874,000) |
| Total stockholders’ equity | 4,226,651,000 | 3,770,004,000 |
| Total liabilities and stockholders’ equity | $ 5,510,214,000 | $ 4,933,352,000 |